Clinical trials: Etoposide, completed
Small Cell Lung Cancer
Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Background: The effect of existing treatment modalities of extensive disease small-cell lung cancer (ED-SCLC) is unsatisfactory. Progress of new strategies including more efficient therapy is wanted.
- Trial name
- NCT00912392
- Testing
- Endostar, Etoposide-Carboplatin
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Sarcoma
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006734
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 239 sites in United States, Australia and 5 more
- Volunteers
- 587 people
- Sponsor
- Children's Oncology Group
Small Cell Lung Cancer
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and…
- Trial name
- NCT02499770
- Testing
- Carboplatin, Trilaciclib, Etoposide
- Where
- 40 sites in United States, France and 5 more
- Volunteers
- 122 people
- Sponsor
- G1 Therapeutics, Inc.
Neoplasms, Unknown Primary
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with…
- Trial name
- NCT00193596
- Testing
- Etoposide, Gemcitabine, Irinotecan
- Where
- 31 sites in United States
- Volunteers
- 198 people
- Sponsor
- SCRI Development Innovations, LLC
Acute Lymphoblastic Leukemia
LAL-BR/2001: Study Treatment to Low Risk ALL
The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease
- Trial name
- NCT00526175
- Testing
- Prednisone, Vincristine, Daunorubicin
- Where
- 25 sites in Spain
- Volunteers
- 150 people
- Sponsor
- PETHEMA Foundation
Central Nervous System Tumor, Pediatric, Leukemia
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00357500
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Dana-Farber Cancer Institute
Hodgkin Lymphoma
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
The choice of a preferred first-line treatment requires balancing the desire for optimal disease control with the occurrence of early and late treatment-related effects.
- Trial name
- NCT01251107
- Testing
- Bleomycin, Etoposide, Doxorubicin
- Where
- Italy
- Volunteers
- 331 people
- Sponsor
- Fondazione Michelangelo
Hodgkin Lymphoma
PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma
Nivolumab is an anti-PD-1 antibody with high activity in patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL).
- Trial name
- NICE-40 (NCT04981899)
- Testing
- Nivolumab, Ifosfamide, Carboplatin
- Where
- 5 sites in Russia
- Volunteers
- 37 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Hodgkin Disease, Lymphoma, Non-Hodgkin
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
Phase II study is being conducted to confirm the safety and efficacy of high-dose Melphalan HCl for Injection (Propylene Glycol-Free) when included in the BEAM regimen for myeloablative conditioning in lymphoma patients…
- Trial name
- NCT01969435
- Testing
- Carmustine, Etoposide phosphate, Cytarabine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Brain Tumor Recurrent
Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children with Recurrent Posterior Fossa Brain Tumors
The goal of this clinical research study is to establish the safety of simultaneous infusions of methotrexate and etoposide into the fourth ventricle of the brain or resection cavity in patients with recurrent malignant posterior…
- Trial name
- NCT02905110
- Testing
- Methotrexate, Etoposide, Ommaya Reservoir
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Hodgkin's Disease, Non-Hodgkin's Lymphoma
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide.
- Trial name
- SAHA (NCT00691210)
- Testing
- Vorinostat, Niacinamide, Etoposide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004224
- Testing
- cyclophosphamide, etoposide, vincristine sulfate
- Where
- 7 sites in Argentina, Canada and 5 more
- Volunteers
- 65 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Lymphoma
Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous peripheral stem cell transplantation may allow the…
- Trial name
- CBV (NCT00005613)
- Testing
- cyclophosphamide, etoposide, BCNU
- Where
- 2 sites in United States
- Volunteers
- 147 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Limited Stage Small Cell Lung Cancer
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of…
- Trial name
- NCT04952597
- Testing
- Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy
- Where
- 33 sites in United States, China and 1 more
- Volunteers
- 126 people
- Sponsor
- BeiGene
Lymphoma
Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Antiviral therapy may kill viruses such as HTLV-1 that can cause cancer.
- Trial name
- NCT00041327
- Testing
- filgrastim, recombinant interferon alfa, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- AIDS Malignancy Consortium
Acute Lymphobkastic Leukemia
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
Understand the dynamics of elimination of MRD in adult patients with standard-risk LAL treated with a pediatric protocol.
- Trial name
- NCT02036489
- Testing
- Vincristine, Daunorubicin, Prednisone
- Where
- Spain
- Volunteers
- 107 people
- Sponsor
- PETHEMA Foundation
Non-Hodgkin's Lymphoma
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
In order to improve the clinical result of high-dose chemotherapy and autologous stem cell transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning regimen.
- Trial name
- NCT00336843
- Testing
- Zevalin-BuCyE
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Asan Medical Center
AML
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
The purpose of this study is to evaluate the addition of Sirolimus (rapamycin) to standard chemotherapy for the treatment of patients with high risk acute myelogenous leukemia (AML).
- Trial name
- NCT01184898
- Testing
- Sirolimus, Mitoxantrone, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lymphoma
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002714
- Testing
- bleomycin sulfate, Stanford V regimen, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Stanford University
Classical Hodgkin Lymphoma
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure…
- Trial name
- NCT02684708
- Testing
- cyclophosphamide, vincristine, prednisone, dacarbazine, cyclo, vcr, pred, dacarb,etop and doxo
- Where
- 19 sites in Australia, Austria and 17 more
- Volunteers
- 2,921 people
- Sponsor
- University of Giessen